Hemostemix Inc. (CVE:HEM – Get Free Report) shares traded up 37.9% during trading on Thursday . The company traded as high as C$0.24 and last traded at C$0.20. 640,100 shares were traded during mid-day trading, an increase of 45% from the average session volume of 440,650 shares. The stock had previously closed at C$0.15.
Hemostemix Trading Up 27.6 %
The company has a market cap of C$16.12 million, a PE ratio of -9.25 and a beta of 0.20. The firm has a 50 day moving average of C$0.09 and a two-hundred day moving average of C$0.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- 3 Small Caps With Big Return Potential
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- The How and Why of Investing in Gold Stocks
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Using the MarketBeat Dividend Yield Calculator
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
